Elodie Amour

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 458 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial

Nicolas Girard, Françoise Mornex, Jean‐Yves Douillard et al. · Lung Cancer · 2009 · 80 citations

Medicine, Oncology, Surgery +17

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier et al. · Journal of Clinical Oncology · 2017 · 51 citations

Medicine, Oncology, Pharmacology +16

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial

Pierre Véra, S. Thureau, F. Le Tinier et al. · The Lancet Oncology · 2024 · 34 citations

Medicine, Oncology, Radiation Oncology +16

First-Line Afatinib plus Cetuximab for <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

Alexis B. Cortot, Anne Madroszyk, Etienne Giroux‐Leprieur et al. · Clinical Cancer Research · 2021 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16